Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...

Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...

Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

A Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with ...